Altnoids in Japan: A Guide to the Current Cannabinoid Landscape

Originally published July 15, 2025 / Last updated September 29, 2026

Japan’s cannabinoid scene moves faster than you can say “CBD latte.” One month, a new acronym is everywhere; the next, it has vanished from shop menus, group chats, and the collective memory of anyone who does not enjoy regulatory paperwork.

This guide tracks cannabinoids, altnoids, and cannabinoid-related terms currently appearing on Japan’s consumer market, including familiar names such as CBD and CBG alongside newer compounds and proprietary blends. Think of it as a living field guide: a way to decode the labels, understand how products are commonly marketed, and figure out which names now belong in the “historical context” drawer.

A quick vocabulary check before we begin: cannabinoids are the broad umbrella, including CBD, CBG, THC, and many others. Altnoids is informal shorthand for newer or alternative cannabinoid products, often made by chemically converting hemp-derived starting materials.

Not every cannabinoid is an altnoid, and not every altnoid is the same kind of thing.

👉 Below you’ll find a snapshot of cannabinoids and altnoids currently appearing on Japan’s consumer market, along with some important names from the recent past.

Just keep in mind that this market can change quickly. Explore with curiosity, read current product information carefully, and always check the date before relying on an older article. And if there’s something I’m missing, please let me know: maryjaneinjapan@gmail.com

⚠️ Important: This page is an independent overview of Japan’s cannabinoid market and is provided for general information only. It is not legal or medical advice, and inclusion here does not constitute a guarantee that any particular ingredient, formulation, or product complies with current Japanese law. Regulations, controlled-substance designations, product formulations, and market availability can change quickly. Always check current official information and current product documentation before purchasing, possessing, or using any cannabinoid product.

Regulatory update: CBN became a designated drug in Japan on June 1, 2026. It is included below for historical context only, not as a current consumer option.

How to Read This Guide

Each entry explains what an ingredient is generally described as, where it comes from, and how brands or users commonly talk about its effects.

Those effect descriptions are not guarantees. Dose, formula, terpenes, tolerance, setting, food, mood, hormones, health, and whether Mercury is in retrograde can all change the experience. Likewise, “currently observed” describes market presence, not a legal determination by Mary Jane in Japan.

For the bigger picture—including the difference between natural, semi-synthetic, and fully synthetic cannabinoids—read: What Are Altnoids?

Non-Intoxicating or Mildly Felt Cannabinoids

These cannabinoids are generally discussed as non-intoxicating, lighter, or more wellness-oriented than stronger-effect altnoids. That does not mean every product will feel identical, especially when brands start mixing several ingredients together.

CBD (Cannabidiol)

Status: Currently observed in Japan
What it is: A major naturally occurring cannabinoid found in hemp.
Origin: Hemp-derived.
Commonly marketed for: Everyday calm, wellness routines, and non-intoxicating products.
What to know: CBD is the familiar starting point for much of Japan’s cannabinoid market. It is generally not intoxicating in the way THC is, but quality, formulation, and documentation can vary significantly between products.
Japan note: Japanese rules governing cannabis-derived products and residual THC are strict. Product origin, formulation, and THC compliance can matter, particularly with imported products. Check current official Japanese guidance and current testing documentation rather than assuming that a product sold legally elsewhere is compliant in Japan.

CBG (Cannabigerol)

Status: Currently observed in Japan
What it is: A naturally occurring cannabinoid often called the “mother cannabinoid,” because it is a precursor in the plant’s cannabinoid pathway.
Origin: Hemp-derived.
Commonly marketed for: Clear, daytime-friendly, focused-calm vibes.
What to know: CBG is often blended with CBD rather than sold on its own. It is commonly positioned as a lighter, more alert counterpart to CBD, although the whole formula matters more than the name.

CBN (Cannabinol)*

Status: *Historical context — regulated (illegal for possession and use) in Japan from June 1, 2026
What it is: A cannabinoid associated with the breakdown or oxidation of THC.
Origin: Naturally occurring in cannabis, often discussed in relation to aged THC.
Previously marketed for: Nighttime relaxation, sleep-oriented blends, and a heavier wind-down feel.
What to know: CBN was a major name in Japan’s cannabinoid market until its designation in 2026. It remains here because readers will still encounter it in older reviews, product pages, and screenshots from the Before Times.
Japan note: Do not treat older CBN listings or reviews as evidence of its current regulatory status or as current consumer recommendations.

CRD

Status: Currently observed in Japan
What it is: CRD is generally used to describe a stabilized cannabinoid distillate designed to resist, and help products resist crystallization.
Origin: Blend distillate; formulas can include different cannabinoids depending on the supplier.
Commonly marketed for: A balanced cannabinoid experience shaped by the specific blend.
What to know: CRD generally describes a stabilized cannabinoid distillate blend rather than one single cannabinoid. The exact ingredients and ratios can differ by product, so check the label or COA to see what is actually in a particular formulation.

H4CBD (Hydrogenated Cannabidiol)

Status: Currently observed in Japan
What it is: A hydrogenated CBD-derived cannabinoid.
Origin: Commonly described as semi-synthetic, made from hemp-derived CBD.
Commonly marketed for: A fuller, more noticeable cannabinoid experience than standard CBD.
What to know: H4CBD is a hydrogenated CBD-derived cannabinoid. In Japan, it has appeared in products such as vapes and cannabinoid blends.
Mary Jane’s translation: CBD’s slightly more dressed-up cousin—not an automatic ticket to a THC-style high.

Read more: What is H4CBD?

Stronger-Effect / Psychoactive Altnoids

These are ingredients and blends commonly marketed or described by users as producing more noticeable psychoactive, euphoric, body-heavy, or “THC-like intoxication”. That does not mean every product is equally strong, and experiences can vary substantially between products and individuals. Market presence should also not be interpreted as confirmation of current regulatory status in Japan.

THCNM/THA

Status: Currently observed in Japan as THCNM; previously marketed as THA.
What it is: A psychoactive cannabinoid identified by BudsBrain as 1′-Dimethyl-Delta-9-THCH, related to THCH. THA was a commercial name for blends containing THCNM.
Origin: Reportedly sourced from the Netherlands, although suppliers and formulations may vary.
Commonly marketed or reported as: Euphoric, uplifting, and relatively clear-headed, with balanced sativa- and indica-like effects, noticeable psychoactivity, and possible appetite stimulation.
What to know: Independent research on potency, safety, and duration remains limited. BudsBrain reports that a specific THCNM material was assessed as not being a narcotic under Japanese law, but this doesn’t establish blanket legality. Check current regulations and product COAs.

Read more: What is THCNM?

CBX

Status: Currently observed in Japan
What it is: A newer converted cannabinoid material appearing in Japan as isolate and distillate. Sellers describe it as a C4-series material, made from hemp-derived cannabinoid starting materials through chemical conversion and purification.
Commonly marketed or reported as: Fast-onset, noticeable, clear and sativa-leaning, with a relatively quick, clean finish.
What to know: CBX is still very new, with limited public research and inconsistent disclosure of its exact composition. Do not assume every CBX-labelled product contains the same compounds or will feel the same.

Read more: What Is CBX?

THAH

Status: Currently observed in Japan
What it is: A newer cannabinoid ingredient that began appearing in Japan in 2026. It is unrelated to THA, despite the similar names.
Origin: Reportedly a newer imported raw material or a blended raw material; nobody is saying for sure, and exact supplier details can vary by product.
Commonly marketed or reported as: Slow-building euphoric head effects, deep body relaxation, and couch-lock territory.
What to know: Brands have positioned THAH as a stronger option for experienced users, with effects that may build over 20–30 minutes.

Read more: What is THAH?

CPX and HHBD

Status: Currently observed in Japan
What it is: Newer CBD-derived cannabinoid ingredients often used in stronger-effect formulas.
Origin: Commonly described as lab-converted from hemp-derived starting materials; terminology can vary by seller.
Commonly marketed or reported as: Clearer, more daytime-friendly effects with a euphoric lift and a relaxed body feel.
What to know: CPX and HHBD are often presented as “functional” or “sativa-like” options, but the blend, percentage, and terpene profile can change the actual experience dramatically.

Read more: What is HHBD?

CRDP

Status: Currently observed in Japan
What it is: A psychoactive cannabinoid blend that became especially visible in Japan after first appearing in Thailand.
Origin: Developed in Thailand; commonly described as hemp-derived but chemically modified.
Commonly marketed or reported as: Uplifting, euphoric, moderate-to-strong effects, often with a heavier body component.
What to know: CRDP is frequently used in stronger vape formulas.

Read more: What is CRDP?

CRDB

Status: Currently observed in Japan/market terminology varies
What it is: A CRD-style blend featuring four-carbon-chain compounds, developed as a clearer alternative to CRDP.
Origin: Lab-produced from hemp-derived cannabinoids; reportedly from the same manufacturer family as CRDP.
Commonly marketed or reported as: Fast onset, uplifting and focus-friendly at first, then a smoother hybrid-style calm.
What to know: It is a newer, supplier-led label, so check the exact product formula and COA rather than treating the name as a universal standard.

Read more: What is CRDB?

H4CBH

Status: Currently observed in Japan
What it is: A hydrogenated cannabinoid related to the HHC family, with its own modifications.
Origin: Lab-modified from hemp-derived starting materials.
Commonly marketed or reported as: Brighter, more social, head-forward, and one of the stronger altnoids on the market at the time of writing.
What to know: H4CBH has earned a reputation as one of the stronger-feeling newer ingredients in Japan. Experiences vary, and the percentage on a label is not the whole story.

Read more: What is H4CBH?

Historical Market Listings / Now-Regulated Ingredients

These names are included because you may still encounter them in older reviews, archived product pages, search results, or the occasional screenshot from someone’s 2024 group chat.

They are not a current-use list, and their inclusion here should not be interpreted as an indication of current legality or availability.

CBN

Status: Designated drug in Japan from June 1, 2026
Previously marketed for: Nighttime relaxation and sleep-oriented blends
Japan’s Ministry of Health, Labour and Welfare designated CBN as a designated drug effective June 1, 2026. As a result, ordinary manufacture, import, sale, possession, and use are prohibited in Japan. Older articles and product listings therefore should not be treated as current consumer information.

HHC, HHCH, THCH and THCPO

Status: Previously appeared on Japan’s consumer market; subsequently regulated
What to know: These compounds were part of an earlier wave of stronger-effect cannabinoids that helped shape Japan’s altnoid market. Their regulation is a reminder that “available now” is not the same thing as “available forever.”

THA

Status: No longer observed following the June 2026 CBN-related regulatory change and associated product withdrawals.
What to know: THA was a blended raw material rather than one single cannabinoid and appeared in a number of products before the regulatory shift.

Quick Q&A: Altnoids in Japan

Q: Does appearing on this page mean a cannabinoid is legal in Japan?
A: Everything included as a current market listing is something I understand, based on the information available to me at the time of writing or updating, to be legally marketed in Japan. I do not knowingly feature prohibited substances as current consumer options.

That said, inclusion in this guide is not a legal determination or guarantee of compliance. Japan’s regulations can change quickly, and individual products sold under the same ingredient name may have different formulations. Always check current official information and current product documentation before purchasing, possessing, or using any cannabinoid product. Ingredients that have since been regulated may remain in this guide for historical context only and will be clearly identified as such.

Q: What’s the difference between non‑psychoactive and psychoactive altnoids?
A: Non-intoxicating or mildly felt cannabinoids such as CBD and CBG are generally discussed as not producing a classic THC-style high. Stronger-effect altnoids may be marketed or described as more euphoric, body-heavy, or perception-shifting. The line is not always perfectly neat, though: dose, formulation, blends, and individual sensitivity all matter.

Q: Where do these cannabinoids come from?
A: Some cannabinoids occur naturally in hemp or cannabis. Others are made by chemically converting hemp-derived starting materials, while some are proprietary blends sold under supplier-specific names. The more mysterious the name, the more important it becomes to look at the actual product documentation rather than assuming the name tells you everything.

Q: Can the regulatory status of these ingredients change?
A: Yes. Japan’s cannabinoid market and regulatory landscape can change quickly. Ingredients that previously appeared openly on the consumer market have subsequently been regulated, which is why this article is dated and periodically updated.

Always check current official information rather than relying on an older article or product listing to determine the current status of an ingredient.

The Bottom Line

Japan’s altnoid market is fascinating, creative, occasionally bewildering, and never especially good at choosing names that are easy to pronounce after one coffee. Fortunately, you do not need to memorize every acronym.

The useful part is understanding the broad difference between lighter cannabinoids and stronger-effect altnoids, knowing that supplier terminology does not always tell the whole story, reading current product documentation, and checking the date before assuming that yesterday’s market still looks like today’s.

This guide is intended to document that changing landscape, not to certify the legal status of individual products or tell anyone what to buy.

If you’ve spotted a cannabinoid or new market term appearing in Japan that you think belongs in this guide, email me at maryjaneinjapan@gmail.com. I can’t promise I’ll add every mysterious letter-combo immediately, but I’m always curious.

Stay curious, stay safe, and stay legally lifted. 🍃

Last updated: September 29, 2026

What Is THCNM (THA)? Japan’s New Cannabinoid Has a Familiar PastOctober 28, 2026Mary Jane

レビュー: Knockout REAL vs. REAL EXPERT – 強ければ本当にいいの？November 12, 2026Mary Jane

Altnoids in Japan: A Guide to the Current Cannabinoid LandscapeJuly 15, 2025Mary Jane